Videos

Health system pharmacists discuss the impact and management of drug shortages, such as fentanyl, midazolam, and propofol, at their institutions during the pandemic.

The panel of experts discuss features of IV infusion pumps found to be most beneficial, especially during the pandemic, such as wireless technologies.

Michael Epshteyn, PharmD, MSM, and Estela Trimino, PharmD, BCPS, share what led to automated IV workflow system use and how it aids in pharmacy’s response to COVID-19.

Advice for clinical pharmacists who help manage patients with relapsed/refractory multiple myeloma in the current era of novel therapies and recommendations to improve upon current practice patterns.

Novel treatment strategies being explored in clinical trials that look exciting in relapsed/refractory multiple myeloma, and implications for using these newer approaches in the future.

The importance of coordinated care and proper education to pharmacists on best practices when dispensing anti-BMCA therapy to patients with relapsed/refractory multiple myeloma.

Health-system pharmacists discuss the role pharmacy played within their health-systems in response to COVID-19, and the impact of COVID-19 on implementation urgency.

Pharmacy Times spoke with Josh Benner, pharmacist and CEO/founder of RxAnte, about medication misuse and the future of pharmacy in 2021.

Caroline Carney, MD, MSc, FAPM, CPHQ, CMO of Magellan Health, discusses how pharmacists and other medical professionals can boost their brain health and keep a positive mindset while working during the pandemic.

Farah Towfic, PharmD, MBA, director, CEO operations at US Pharmacopeia (USP), discusses USP’s release of an updated version of its COVID-19 Vaccine Handling Toolkit in response to feedback from independent pharmacies to mass vaccination clinics.

Theresa Mallick-Searle, MS, RN-BC, ANP-BC, shares her perspective on the new labeling requirements put forth by the FDA for opioids in regard to naloxone.

Joshua Lynch, DO, EMT-P, FAAEM, FACEP, highlight risks he has seen in the community for unintended users as well as patients for accidental opioid overdose.

Caroline Carney, MD, MSc, FAPM, CPHQ, CMO of Magellan Health, discusses how pharmacists can be first line in noticing changes in patients’ cognitive functioning.

This week is National Brain Awareness Week, so Pharmacy Times® interviewed Caroline Carney, MD, MSc, FAPM, CPHQ, CMO of Magellan Health, on some of the issues surrounding the contemporary understanding of mental health and brain health.

Pharmacy Times® interviewed George Rafferty, president of corporate partnerships at AmerisourceBergen, on how large retail pharmacies have been impacted by and been able to respond to the challenges of the COVID-19 pandemic.

Jeffrey Bratberg, PharmD, FAPhA, leads discussion tackling common opioid-related misconceptions as well as unintended consequences of the opioid crisis.

Jeremy Adler, DMSc, PA-C, DFAAPA, leads discussion on elements that negatively impacts the quality of care for patients requiring pain management.

A panel of experts in the management of NETs discuss the role of peptide receptor radionuclide therapy for NETs.

Pharmacy Times® interviewed Beth Battaglino, RN-C, CEO of HealthyWomen and a convener of the COVID-19 Vaccine Education and Equity Project, on the recent “Count Me In” digital campaign.

Robert Mancini, PharmD, BCOP, FHOPA, of St. Luke’s Cancer Institute: Boise, comments on his experience navigating challenges using belantamab mafodotin, an anti-BCMA therapy, to treat relapsed/refractory multiple myeloma.

Recommendations for managing patients who receive belantamab mafodotin, an anti-BCMA therapy, for relapsed/refractory multiple myeloma, with special considerations regarding the ocular health of patients.

Following the establishment of the Federal Retail Pharmacy Program by the CDC, a panel of experts sat down with Pharmacy Times® to address the implications of the Federal Retail Pharmacy Program for COVID-19 vaccinations.

Experts in the management of VTE discuss the deterrents among providers, patients, and pharmacists, specifically looking at the various dosage forms of treatment.

A panel of experts discuss the risks vs benefits of prophylactic care for patients to prevent VTE.

Best practices for prescribing an immunomodulatory-based therapy or a proteasome inhibitor as treatment for relapsed/refractory multiple myeloma.

Considerations for treating patients with relapsed/refractory multiple myeloma with elotuzumab, daratumumab, or isatuximab based on more recent clinical trial data and differences between each treatment option.

Variables considered by healthcare professionals when selecting an appropriate backbone regimen to manage a patient with relapsed or refractory multiple myeloma.

Healthcare stakeholders comment on current practices managing patients with relapsed/refractory multiple myeloma during the COVID pandemic and discuss their comfort switching patients over from intravenous daratumumab to subcutaneous daratumumab.

Factors that influence treatment selection for relapsed or refractory multiple myeloma, and suggestions to help streamline decision making and address limitations associated with current treatment pathways.

A historical review of treatment advances in relapsed/refractory multiple myeloma and criteria used to define relapsed or refractory disease.